Proud to announce the launch of Toripalimab in India, the first and only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Toripalimab is a New Biological Entity (NBE). The combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death, meeting a significant unmet need for patients with RM-NPC in a disease that previously had very poor prognosis.
Combination of Toripalimab and standard of care chemotherapy has shown a 48%reduction in risk of progression or death
Launched in India in the same year as its launch in the U.S., making India the third country in the world to receive access to this New Biological Entity (NBE)
With this launch by Dr. Reddy’s, India becomes the 3rd country in the world to receive access to this next generation PD-1 inhibitor. Under our innovation agenda, ‘access to novel molecules’ through collaborations is a key pillar. Access to meaningful innovation and the latest standard of care remains a challenge for patients in emerging markets. Thanks to the relentless efforts of our cross-functional teams, we have been able to launch Toripalimab in India in the same year as its launch in the U.S.
Oncology has been a top focus therapy area for us. Our offerings aim to build an end-to-end ecosystem of care access to current standard of care cancer medicines across multiple countries globally, innovation in formulations, strategic collaborations for novel innovative molecules particularly in India and other emerging markets, beyond-the-pill support such as nutrition and digital tools. Our portfolio of standard of care small molecules and biosimilars across cancer types in India and other emerging markets has included RedituxTM, Versavo, Lenangio TM, and Hervycta.
